NCT05665192View on ClinicalTrials.gov

A Study to Assess Real-World Patient-Reported Outcomes With Fedratinib for Myelofibrosis Post-Ruxolitinib

CompletedOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

August 2, 2021

Primary Completion Date

July 24, 2023

Study Completion Date

July 24, 2023

Conditions
Myelofibrosis
Trial Locations (1)

43017

Cardinal Health Specialty Solutions, Dublin

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY